BioCryst Pharmaceuticals
BCRX
233 hedge funds and large institutions have $1.24B invested in BioCryst Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 101 increasing their positions, 57 reducing their positions, and 22 closing their positions.
287% more call options, than puts
Call options by funds: $22.4M | Put options by funds: $5.79M
77% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 57
1% more capital invested
Capital invested by funds: $1.23B → $1.24B (+$18.3M)
0.61% more ownership
Funds ownership: 92.14% → 92.75% (+0.61%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
5% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 22
1% less funds holding
Funds holding: 236 → 233 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$18.5M |
| 2 |
DM
Deerfield Management
New York
|
+$14.1M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$11.3M |
| 4 |
BlackRock
New York
|
+$9.19M |
| 5 |
Morgan Stanley
New York
|
+$6.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$30.3M |
| 2 |
State Street
Boston,
Massachusetts
|
-$12.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.95M |
| 4 |
Fisher Asset Management
Camas,
Washington
|
-$8.19M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$4.93M |
BCRX Hedge Fund Activity: Q3 2023 in Review
233 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2023, worth a combined $1.24B — up 1.5% from $1.23B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of BCRX and 21 opened new positions — a net loss of 1 holder — while 57 trimmed existing stakes and 101 added.
The largest buyer was Braidwell, adding an estimated $18.5M. The largest seller was Assenagon Asset Management, cutting an estimated $30.3M.
- 233 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2023, down from 236 in Q2 2023.
- Funds reported $1.24B of BioCryst Pharmaceuticals stock for Q3 2023, up 1.5% quarter-over-quarter.
- 21 funds opened new BioCryst Pharmaceuticals positions in Q3 2023 and 22 closed out, a net change of -1 holder.
- The largest BioCryst Pharmaceuticals buyer in Q3 2023 was Braidwell, an estimated $18.5M added.
- The largest BioCryst Pharmaceuticals seller in Q3 2023 was Assenagon Asset Management, an estimated $30.3M sold.
Based on aggregated 13F filings for Q3 2023.